Cambrian BioPharma Inc

SEC source: 0000897069-26-001299 · form4.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,142

SEC source: 0000897069-26-001299 · form4.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,618

F1 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $20.00 to $21.00. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000897069-25-001795 · form4.xml · derivative · entry 6

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 395 shares

Expires 2035-05-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · shares: The amount shown reflects the number of shares held following the reported transaction, as adjusted for a 1-for-20 stock split effectuated by the issuer.

F6 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0000897069-25-001795 · form4.xml · nonDerivative · entry 5

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,142

F4 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $7.91 to $7.95. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001795 · form4.xml · nonDerivative · entry 4

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,588

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001795 · form4.xml · nonDerivative · entry 3

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,983

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001795 · form4.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,588

F3 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $7.80 to $8.33. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001795 · form4.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 158,254

F1 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $8.50 to $9.00. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001776 · form4.xml · nonDerivative · entry 4

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,359

F6 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $13.00 to $13.26. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001776 · form4.xml · nonDerivative · entry 3

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,401

F5 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $12.02 to $12.95. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001776 · form4.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 163,146

F4 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $11.00 to $12.00. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-25-001776 · form4.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 177,654

F1 · price: The price reported in Column 4 is a weighted average price. The prices sold ranged from $9.00 to $9.54. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · balance_after: The amount shown reflects the number of shares held following the reported transaction, as adjusted for a 1-for-20 stock split effectuated by the issuer.

F3 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001415889-25-014485 · form4-05232025_040514.xml · derivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2035-05-20

F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001415889-24-016699 · form4-06132024_090650.xml · derivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 19,000 shares

Expires 2034-06-10

F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 11, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0000897069-23-001054 · form4.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,653,120

F1 · shares: Shares purchased by the Issuer pursuant to a Purchase Agreement, dated July 31, 2023, by and among the Issuer, the Reporting Person and James Peyer. This transaction, which was approved by the Board of Directors of the Issuer, is exempt pursuant to Rule 16b-3(e) of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001209191-23-042076 · doc4.xml · derivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,550

Underlying: Common Stock · 14,550 shares

Expires 2033-07-09

F3 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or July 10, 2024, subject to James Peyer's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to James Peyer's continuous service with the Issuer through such vesting date.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001209191-23-042076 · doc4.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,240,422

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or July 10, 2024, subject to the James Peyer's continuous service with the Issuer through such vesting date.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-012842 · doc1.xml · derivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,550

Underlying: Common Stock · 14,550 shares

Expires 2032-06-09

F3 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 10, 2023, subject to the James Peyer's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the James Peyer's continuous service with the Issuer through such vesting date.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-012842 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,235,954

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or June 10, 2023, subject to the James Peyer's continuous service with the Issuer through such vesting date.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-23-004608 · doc1.xml · derivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,550

Underlying: Common Stock · 14,550 shares

Expires 2032-06-09

F3 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 10, 2023, subject to the James Peyer's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the James Peyer's continuous service with the Issuer through such vesting date.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-23-004608 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,235,956

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or June 10, 2023, subject to the James Peyer's continuous service with the Issuer through such vesting date.

F4 · balance_after: Amendment filed solely to correct the number of shares owned.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-006007 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,231,989

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-012646 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,231,488

F1 · balance_after: This Form 4/A is being filed solely to correct the number of shares beneficially owned following the transaction reported herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-005913 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,230,786

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-005913 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,228,328

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-005791 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,228,286

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-005518 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,225,786

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-005518 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,210,786

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-005190 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,208,286

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.85 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-005190 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,193,286

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.15 to $4.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-004779 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,188,337

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.20 to $4.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-004779 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,185,786

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.10 to $4.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-004543 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,175,786

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.30 to $4.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-004543 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,163,286

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.55 to $4.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-002937 · doc1.xml · nonDerivative · entry 3

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,158,286

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.25 to $4.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-002937 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,148,286

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-002937 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,145,786

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.50 to $4.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-002036 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,128,286

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.15 to $4.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-002036 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,119,386

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.25 to $4.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001801 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,113,286

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.50 to $4.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001801 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,083,386

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.75 to $4.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001632 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,063,286

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.60 to $4.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001632 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,040,579

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.80 to $5.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001462 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,015,876

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.10 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001462 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,995,876

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.90 to $5.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001340 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,985,632

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.05 to $5.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001228 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,975,632

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.95 to $5.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001228 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,969,413

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.05 to $5.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001165 · doc1.xml · nonDerivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,949,460

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.20 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-001165 · doc1.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,940,258

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.10 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.